Background New treatments for atrial fibrillation patients have been shown to be effective at reducing subsequent vascular event recurrence. However, there are few data on stroke costs in atrial fibrillation patients to allow the costeffectiveness of these treatments to be assessed. Aims Using data from a population-based study, we assessed the acute and long-term costs of stroke in atrial fibrillation patients. Methods Health-care costs one-year before and five-years after stroke were obtained from a large population-based study (Oxford Vascular study). Costs were assessed for the three-months poststroke (acute period) and annually thereafter (postacute period). Annual postacute costs were compared with annual baseline costs. Based on patients' living arrangements, costs of institutionalization after the event were included. Results A total of 191 strokes occurred in 153 patients with known prior atrial fibrillation. Mean health-care costs after stroke were £10 413 (standard deviation 15 105) in the acute phase, with annual postacute health-care costs nonsignificantly smaller than those incurred before the event (£2400 vs. £3356, respectively; P = 0·198). However, for the 136 strokes surviving past the 90-day acute period, costs were nonsignificantly higher than those incurred in the year before the event (£3370 vs. £2566, respectively; P = 0·333). After stroke, 25 (13%) patients were newly admitted into long-term warden, nursing, or residential care, resulting in annual costs of £6880 (standard deviation 15 600) averaged across the 136 stroke cases surviving past the acute period. Conclusions Although annual post acute phase hospital and primary health-care costs in stroke patients with prior atrial fibrillation were not significantly different to those incurred before the stroke, long-term nursing/residential care costs were substantial.
Introduction
Stroke was estimated to cost the UK health care system £5 billion in 2004 (1) . Case fatality is about 20% (2) , with 50% of survivors being disabled one-year after stroke (3) . Outcome is particularly adverse in the 20% of patients who have stroke with a history of atrial fibrillation (AF) (4-6) for these patients' acute health-care costs are increased (5, 6) . Standard care for AF patients is treatment with vitamin K antagonists such as warfarin (7, 8) . However, results from recent randomized controlled trials of direct thrombin inhibitors and factor Xa inhibitors have found these new treatments to be as or more effective than warfarin at reducing thromboembolic events despite having a lower risk of intracranial bleeding and no greater risk of gastrointestinal bleeding than warfarin (9, 10) . These new agents could therefore improve the effectiveness of stroke prevention in patients with AF, but costeffectiveness must also be taken into account (11) . Estimates of cost-effectiveness are often based on decision-analytic models that use estimates of the cost of outcomes prevented and of effectiveness from randomized controlled trials (12) .
For cost-effectiveness results to be valid and reliable, model inputs, such as costs and outcomes, must be derived from appropriate sources using adequate methodologies. A recent systematic review of studies of the costs of stroke found relatively few studies in which costs of stroke in patients with AF had been assessed and no studies of costs beyond the acute stage (13) . We aimed therefore to determine the acute and longer term health-care costs of stroke in patients with a history of AF, including the costs of long-term institutionalization, using data from a population-based study (Oxford Vascular Study, OXVASC). It is generally considered that population-based studies with full case ascertainment are the most accurate sources of information on disease incidence, mortality, and outcome (14) .
Methods
The methods of OXVASC have already been described (15) . Briefly, the population is composed of over 91 000 patients registered with 63 family doctors in nine Oxfordshire general practices. Patients with suspected stroke were identified and considered for study inclusion. Although study recruitment is ongoing, only stroke patients recruited in the first five-years of the study (1 April 2002 to 31 March 2007 were included in the analysis in order to allow sufficient follow-up to estimate longer term costs reliably.
Ascertainment was by prospective daily searches for acute events and retrospective searches of hospital and primary care administrative records (15) . Suspected stroke patients were assessed urgently by a study clinician. Informed consent was sought, and assessments of neurological impairment, history, and timing of presentation, medical and social history, and risk factors were performed. The current study was confined to those patients in whom a diagnosis of AF (paroxysmal or permanent) had been made prior to the stroke, irrespective of any antithrombotic treatment. Using information on patients' age and history of stroke, transient ischemic attack, hypertension, congestive heart failure, and diabetes, CHADS2 (Congestive Heart Failure, Hypertension, Age > 75 years, Diabetes mellitus, and prior Stroke or TIA) scores were calculated and used to estimate the risk of stroke (16) . Surviving patients were followed-up at one-month, six-months, and 12, 24, and 60 months after the event. At follow-up, among other outcomes, patients' living arrangements and handicap were assessed, with the latter being measured using the modified Rankin Score (mRS) (17) .
Health-care resource use
Patients were followed up from the time of event until death or end of follow-up at five-years. For patients not reaching the five-year follow-up, follow-up finished on 30 January 2010. Our methods of identification of resource use in the acute phase after stroke have been reported previously (6) . In addition, patients' computerized hospital and primary care records were reviewed, with resources consumed within the 12 months prior to the event also being obtained. Hospital resource use evaluated included accident and emergency (A&E) visits, emergency transport, outpatient care visits, day cases, and hospitalizations, including community hospitals. Primary care resource use included home, surgery, and telephone consultations with nurses or general practitioners (GPs).
Hospital records contained information on the date of outpatient visits, specialty, and whether it was a new or follow-up visit. Visits for diagnostic investigations were also obtained. For each spell in hospital, the date of admission and discharge was recorded, including dates of transfers between wards and their medical specialty. Hospitalizations were defined as spells in which the patient was admitted for at least one night. Length of stay was calculated as the number of days between admission and discharge. A day case was recorded when the date of discharge was the same as that of admission.
As part of the study, patients were asked about their living arrangements at follow-up and at initial ascertainment. Living arrangements were categorized as own home, relatives'/ friends' home, warden housing, and long-term residential or nursing home care. Resource use was priced using unit costs, with all costs being valued in 2008/2009 UK pounds sterling (£). When unit costs were obtained from sources detailing costs before 2008/2009, costs were updated using the Hospital and Community Health Services pay and price inflation index (18) . Outpatient visits, outpatient investigations, and A&E visits were priced using unit costs derived from National Health Service (NHS) reference costs (19) . For each hospital ward, the unit costs per day case/day in a hospital were derived from NHS reference costs and trust financial returns (19, 20) . Only for the cost of stroke unit care was the unit cost derived from published studies (6, 21) . Unit costs of emergency transport and primary care visits were obtained from a UK compendium on the costs of health-and social care, which also provided information on the costs of warden housing and long-term nursing home and residential home care (18) .
Statistical analyses
Patients with AF may have multiple strokes (22) . Consequently, assessing the mean cost per patient could potentially include the costs of more than one cerebrovascular event. To better assess the individual cost of the stroke, the unit of analysis in this study was the number of events rather than the number of patients. Therefore, for those patients in the analysis suffering a subsequent stroke, follow-up for the initial event ended at the time of the subsequent event, with the subsequent event being followed up as a new event. In addition, follow-up was also ended for those patients suffering a major coronary event, such as a myocardial infarction (MI). However, when strokes occurred in short succession of each other, it was difficult to separate the costs between the initial event and the subsequent one. As a result, strokes occurring up to 90 days post-first stroke were indexed to the initial event.
Health-care resource use and costs were estimated for the first 90 days after stroke (acute period) and then for the period past this acute period until end of follow-up (postacute period). Costs were stratified in this way as published evidence shows that average health-care costs after stroke are highest in the months immediately after the event, with mean healthcare costs quickly tailing off (23, 24) . However, stroke onset is associated with old age and generally occurs in patients with other comorbidities (15) . Such patients are therefore likely to consume substantial health-care resources even if they had not suffered the event. Health-care resource use and costs incurred during the 12 months before the stroke (baseline period) were therefore compared with the costs incurred in the postacute period after the stroke for all those cases surviving past the acute period. For patients suffering subsequent events, the baseline period used was the 12 months before the initial index stroke. No comparisons were made between baseline and acute period resource use and costs as evidence suggests that shortly after the event, the majority of costs incurred can be directly attributable to the stroke (6) .
For all periods (i.e. before the event, acute, and postacute), emergency and outpatient care visits, day cases, and hospitalizations were treated as count variables and reported as number of visits/hospitalizations per patient per follow-up year, and reported alongside their standard error. Rate differences between the baseline and postacute periods were estimated and reported alongside 95% confidence intervals (CIs), with statistical differences evaluated assuming a Poisson distribution (25) . Total days in hospital and costs for the baseline, acute, and postacute period were also assessed. Days in hospital and costs were reported as means together with their standard deviation (SD). To compare the days in hospital and costs during the year before the event with the days in hospital and costs incurred during the postacute period, the latter were annualized by dividing patients' follow-up days in hospital and costs over the number of years of patient follow-up. Mean differences between the two time periods were reported alongside 95% CI, and statistical differences in mean estimates were evaluated using a Student's two-sided paired t-test. Statistical significance was set at P < 0·050.
The costs of long-term accommodation in warden housing and nursing or residential care were also estimated. For patients already in long-term care at the time of the stroke, costs of long-term care were not included as these were considered to be unrelated to it. For patients moving into longterm care between follow-ups, date of institutionalization was assumed as the midpoint between the two follow-ups or the date of discharge from hospital if patients were still in hospital at that time. Days in warden housing or nursing/residential care home were estimated as the difference between the dates of follow-up and institutionalization, which were then multiplied by the respective unit cost. Days in long-term care and long-term care costs were annualized using the same methods as for postacute health-care costs.
Mean total costs were also reported by event severity. Severity was defined as handicap at six-months, with patients reporting mRS scores lower than 3 being classed as nondisabled, scores of 3 or 4 classed as moderately disabled, and those reporting scores of 5 classed as totally dependent. Patients dying within 30 days of the event were classed as case fatalities. For those patients dying after 30 days but before six-months, stroke severity was defined by mRS at one-month.
Mean total costs were also reported by the estimated risk of suffering a stroke, as defined by the CHADS2 score. Risk of stroke was defined as low for CHADS2 scores of 0, moderate for scores of 1 and 2, and high for scores between 3 and 6 (16).
Results

Patient sample
Between April 2002 and March 2007, 729 patients suffered a stroke as their index event in OXVASC. Of these, 153 (21%) patients had a history of AF and form the basis for this analysis. Patients already had significant comorbidity prior to their index event, with 32 (21%) having a history of MI, 96 (63%) having hypertension, and 30 (21%) being disabled ( Table 1) .
The 153 patients included in the analysis had a total of 191 strokes during the study period. Of these, 162 (85%) were ischemic, 17 (9%) were hemorrhagic strokes, and 12 (6%) were of unknown type. Due to the high mortality rates during the first 90 days after hemorrhagic and unknown strokes, for the analyses of postacute costs, all strokes were combined together. Mean follow-up for each event was 731 (SD 725) days. For the 191 events, end of follow-up occurred due to death in 101 (53%), a subsequent stroke or MI in 41 (21%), and reaching five-year follow-up in 24 (13%), with a further 25 (13%) not reaching five-year follow-up.
Of the 191 strokes, 40 (21%) were fatal within 30 days, 55 by 90 days (acute period), and 65 by six-months (Table 2 ). Of the 25 strokes dying between 90 days and six-months, two (8%) were classed as nondisabling strokes based on one-month mRS, 15 (60%) were classed as moderately disabling, and eight (32%) as totally disabling. For the 126 strokes not resulting in death at six-months, 64 (51%) events were nondisabling based on six-month mRS, 52 (41%) were classed as moderately disabling, and 10 (8%) as totally disabling. Event severity by stroke subtype is reported in Table 2 .
Health-care resource use and costs
Resource use rates by health-care category, including days in hospital, are reported in the supporting information (Table S1 ). For the 191 strokes included in the analysis, the mean hospitalization rate during the acute period was 1·30 per patient per 90-day follow-up, with mean days in hospital for the first 90 days after stroke being 71 (SD 34). Postacutely, for the 136 strokes surviving the postacute phase, the average hospitalization rate was 0·41 per patient per follow-up year, compared with 0·48 before the stroke (mean difference -0·06, 95% CI: -0·07 to -0·05). Although patients spent a higher number of days in hospital postacutely than in the year before the event (seven-vs. five-days), this difference was not statistically significant (mean difference: two-days; 95% CI: -3 to 6; P = 0·529).
For the 191 strokes included in the analysis, the mean total cost incurred during the three-month acute phase was £10 413 (SD 15 105) ( Table 3 ). The majority of these costs were due to hospitalizations (£9841), accounting for 95% of all health-care costs. Costs after stroke rose sharply with event severity, with mean costs per nondisabling stroke of £3945 (SD 7558) compared with £17 406 (SD 18 417) and £25 279 (SD 16 397) for moderately and totally disabling strokes, respectively. The mean costs for case fatal strokes were lower at £2680 (SD 2661) due to the short interval between event and death (mean of nine-days, SD 9). Table 3 also presents acute health-care costs stratified by stroke subtype.
At baseline, mean annual costs were £1753 (SD 2946), £3339 (SD 8603), and £3304 (SD 9474) before the nondisabling, moderately disabling, and totally disabling stroke, respectively. A total of 55 stroke patients did not survive past the acute phase. In the year before the stroke, these patients incurred higher annual average costs than those surviving past the acute phase (£5308 vs. £2566), although this difference did not reach statistical significance (P = 0·072).
For the 136 strokes surviving past the acute period, regardless of event severity, annual postacute costs were nonsignificantly higher than those incurred in the year before the event ( Table 4 ). Only for GP and emergency care was there a significant difference in costs between the two periods. Although more severe strokes incurred higher costs than less severe ones postacutely [nondisabling £2135 (SD 3675) per follow-up year, moderately disabling £4165 (SD 7668), and totally disabling £6324 (SD 14 898)], more severe stroke patients were also incurring higher costs at baseline, mainly due to higher levels of baseline disability and comorbidities. Due to 55 patients dying during the first 90 days past the stroke (i.e. acute phase), annual average postacute costs were £2400 (SD 6223) if estimated over the 191 strokes included in the analysis. This was nonsignificantly lower than the average annual costs, £3356 (SD 7952), incurred before the event by the same patients (mean difference: -£956; 95% CI: -£2393 to £480; P = 0·198).
Long-term nursing and residential care
Of the 191 strokes included in the analysis, 11 (6%) occurred while the patient was already living in long-term care accommodation (three warden housing and eight nursing home care). Of the 136 stroke cases surviving past the acute period, 25 (18%) strokes resulted in new long-term care institutionalization (two in warden housing, seven in residential care, and 16 in nursing home care). Long-term care institutionalization varied considerably by event severity. Of the 66 nondisabling strokes, four (6%) were institutionalized, compared with 15 out of the 58 (26%) moderately disabling strokes, and 50% for totally disabling strokes (six out of the 12 totally disabling strokes). On average, newly institutionalized stroke patients spent 365 (SD n/a), 313 (SD 66), and 267 (SD 132) days in warden housing, nursing home care, and residential care, respectively, per follow-up year after the stroke.
Averaged across all stroke cases surviving the acute period (n = 136), new institutionalization after stroke resulted in an average annual stay in long-term care of 56 (SD 124) days. This resulted in average annual costs of £6880 (SD 15 600) poststroke. As with health-care costs, costs of long-term care increased considerably with event severity. For the 66 nondisabling strokes, average costs of long-term care were £942 (SD 3765) for each follow-up year after stroke, compared with £10 646 (SD 19 068) for moderately disabling strokes (n = 58), and £21 335 (SD 22 463) for totally disabling strokes (n = 12).
Health-and social care costs were not closely related to premorbid CHADS2 score (supporting information, Table S2 ).
Discussion
Previous studies have shown that average costs of stroke in patients with AF are higher than those without the condition. In a hospital-based study, Diringer et al. found that the main predictors of costs included neurological impairment, heparin treatment, presence of AF, female gender, and ischemic heart disease (5) . Luengo-Fernandez et al. found that the acute care costs of stroke were significantly higher in patients with AF, but the association disappeared after controlling for event severity (6) . Both these studies, however, only assessed costs during the acute care phase and did not estimate long-term costs.
Our study aimed to assess acute and long-term health-care costs after stroke in patients with AF. In addition, the costs of long-term care institutionalization were also considered. Our results show that in patients with AF, average acute care costs of stroke were £10 413, with costs increasing considerably with event severity. After the acute phase, stroke patients incurred annual health-care costs of £3370, with these costs also varying considerably by event severity.
Since most AF-related stroke occurs in relatively elderly patients, many of whom suffer from previous comorbidities, it is likely that substantial health-care resources would be used irrespective of stroke onset. Therefore, in an attempt to distinguish between costs incurred as a direct result of the stroke and those due to other comorbidities, annual postacute health-care costs were compared with those incurred during the year before the stroke. We found that, overall, annual postacute health-care costs were nonsignificantly higher than those incurred before the event, with only GP and emergency care costs being significantly higher than those at baseline. There was some evidence that those stroke patients not surviving past the acute phase incurred higher costs than those who survived past this period. This would therefore suggest that patients not surviving their stroke tended to be in poorer health than survivors, hence the increased costs incurred before stroke onset.
Health-care services are not, however, the only services that stroke patients utilize. Long-term care institutionalization forms a considerable proportion of costs incurred after stroke (13) . After controlling for patients already living in warden, nursing, or residential care homes, we found that over 10% of patients surviving past the acute stroke phase were newly admitted into long-term care, resulting in annual costs of £6880 after stroke averaged across all patients. This increase in cost also reflects the fact that majority of the AF-related ischemic strokes in our study (158/175) were cardioembolic in etiology (Trial of Org 10172 in Acute Stroke Treatment classification), which are known to be more severe and incur higher mean costs of acute and long-term care (26) .
The limitations of this study should be highlighted. First, not all strokes included in the study were followed up until death or five-years poststroke. A total of 66 (35%) cases were censored, the majority of which was due to follow-up being stopped when the patient suffered either a subsequent stroke or MI (n = 41, 62%). Second, not all health-and social care costs relevant to stroke care were included in the analysis. As with many studies assessing the long-term costs after stroke (13) , potentially considerable costs, such as long-term support of patients living in their own houses (e.g. paid carers and home adaptations), were not included in the analysis. In our analysis, 50% of totally disabling strokes and 74% of moderately disabling strokes were discharged from hospital into the community. As a result, a sizable proportion of these patients would require paid social care. Due to the difficulties in assessing the amount and levels of paid care required by these patients, we were unable to obtain this information. In addition, health-care costs such as those of medications or private hospital care were also omitted from the analysis. Third, due to the small numbers of hemorrhagic strokes, it was difficult to make any meaningful statistical comparisons between stroke subtypes. This was particularly the case when estimating long-term care costs, as the sample size was further diminished due to case fatality. Fourth, our study had a low rate of premorbid anticoagulation use in patients with prior AF. The majority (61%) of our patients who were not on warfarin did not have a clearly documented reason in their medical notes. We were unable therefore to reliably estimate the proportion of costs related to stroke occurring in patients with AF that was unavoidable. However, the low rate of premorbid anticoagulant use in our study is consistent with several other recently published population-based studies (27) (28) (29) , suggesting that our findings are generalizable. Finally, our study only considered the health-and social care costs associated with stroke. No attempt was made to assess indirect costs, such as those associated with relatives or friends providing unpaid care to stroke patients, which have shown to place a considerable economic burden on society (1) .
We believe that our results will be helpful to analysts requiring reliable stroke costs as part of their analyses to estimate the cost-effectiveness of new drugs to prevent stroke in patients with AF. Using a population-based study, our results highlight the considerable costs incurred by stroke patients with AF shortly after stroke. Although annual postacute phase hospital and primary health-care costs in stroke patients with prior AF were not significantly different to those incurred before the stroke, long-term nursing/residential care costs were substantial.
